Evidence map›Paper›PMID 42890318›Full record

ArticleHemaSphere2026

Zanubrutinib monotherapy in

Li Wang, Keshu Zhou, Fei Li, Qingyuan Zhang, Hui Zhou, Ou Bai, Liping Su, Chunhong Hu, Zhi-Ming Li, Kaiyang Ding and 18 more

Abstract readLetter
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Li WangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.ORCID https://orcid.org/0000-0003-2452-0169
Keshu ZhouThe Affiliated Cancer Hospital of Zhengzhou University & HeNan Cancer Hospital Zhengzhou China.ORCID https://orcid.org/0000-0001-5467-1377
Fei LiThe First Affiliated Hospital of Nanchang University Nanchang China.
Qingyuan ZhangHarbin Medical University Cancer Hospital Harbin China.
Hui ZhouHunan Cancer Hospital Changsha China.
Ou BaiThe First Hospital of Jilin University Changchun China.
Liping SuShanxi Provincial Cancer Hospital Taiyuan China.
Chunhong HuThe Second Xiangya Hospital of Central South University Changsha China.
Zhi-Ming LiState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.ORCID https://orcid.org/0000-0001-9730-9917
Kaiyang DingAnhui Provincial Cancer Hospital Hefei China.
Qunyi GuoTaizhou Hospital of Zhejiang Province Taizhou China.
Xiaoling LiLiaoning Cancer Hospital & Institute Shenyang China.
Xiaoxi ZhouTongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan China.ORCID https://orcid.org/0000-0001-9790-859X
Wenjuan YuThe First Affiliated Hospital of Zhejiang University Hangzhou China.
Shuhua YiState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China.ORCID https://orcid.org/0000-0002-6291-812X
Zhixia WeiHainan Cancer Hospital Haikou China.
Wenbin QianZhejiang University College of Medicine-Second Affiliated Hospital Hangzhou China.
Feiheng ChenThe First Affiliated Hospital of Shantou University Medical College Shantou China.
Guohui CuiUnion Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Zhiyu LiangBeOne Medicines, Ltd. Shanghai China.
Qingchao ZengBeOne Medicines, Ltd. Shanghai China.
Jiaoyan LyuBeOne Medicines, Ltd. Beijing China.
Yang LiuBeOne Medicines, Ltd. Shanghai China.
Pan ZhangBeOne Medicines, Ltd. Beijing China.
Zhirong ShenBeOne Medicines, Ltd. Shanghai China.
Zaixing ShiBeOne Medicines, Ltd. Shanghai China.
Jing RongBeOne Medicines, Ltd. Beijing China.
Wei-Li ZhaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.ORCID https://orcid.org/0000-0002-6834-1616

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42890318
PMCPMC13671354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.